Cyclacel Pharmaceuticals Inc. (NASDAQ: CYCC) stock jumped 6.90% on Friday to $1.24 against a previous-day closing price of $1.16. With 1.03 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.75 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $1.2800 whereas the lowest price it dropped to was $1.1750. The 52-week range on CYCC shows that it touched its highest point at $6.10 and its lowest point at $1.01 during that stretch. It currently has a 1-year price target of $20.00. Beta for the stock currently stands at 1.39.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of CYCC was up-trending over the past week, with a rise of 10.71%, but this was up by 14.81% over a month. Three-month performance dropped to -37.06% while six-month performance fell -63.20%. The stock lost -75.15% in the past year, while it has lost -68.12% so far this year. A look at the trailing 12-month EPS for CYCC yields -2.05 with Next year EPS estimates of -3.19. For the next quarter, that number is -0.62. This implies an EPS growth rate of 37.40% for this year and -43.00% for next year.
Float and Shares Shorts:
At present, 9.99 million CYCC shares are outstanding with a float of 9.53 million shares on hand for trading. On Jul 14, 2022, short shares totaled 0.58 million, which was 5.84% higher than short shares on Jun 14, 2022. In addition to Mr. Spiro George Rombotis as the firm’s Pres, CEO & Exec. Director, Mr. Paul McBarron serves as its Exec. VP of Fin., CFO, COO, Sec. & Exec. Director.
Through their ownership of 41.39% of CYCC’s outstanding shares, institutional investors have minority control over the company. Other institutions hold 4.16% of CYCC, in contrast to 24.45% held by mutual funds. Shares owned by individuals account for 2.17%. As the largest shareholder in CYCC with 5.15% of the stake, Schonfeld Strategic Advisors LLC holds 514,780 shares worth 514,780. A second-largest stockholder of CYCC, Sphera Funds Management Ltd., holds 508,322 shares, controlling over 5.09% of the firm’s shares. Sio Capital Management LLC is the third largest shareholder in CYCC, holding 422,598 shares or 4.23% stake. With a 2.20% stake in CYCC, the Vanguard Total Stock Market Index is the largest stakeholder. A total of 220,333 shares are owned by the mutual fund manager. The Vanguard Extended Market Index Fu, which owns about 0.87% of CYCC stock, is the second-largest Mutual Fund holder. It holds 86,789 shares valued at 93732.0. Fidelity Extended Market Index Fu holds 0.39% of the stake in CYCC, owning 39,067 shares worth 42192.0.
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for CYCC since 4 analysts follow the stock currently. There are 4 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With CYCC analysts setting a high price target of $24.00 and a low target of $17.00, the average target price over the next 12 months is $20.00. Based on these targets, CYCC could surge 1835.48% to reach the target high and rise by 1270.97% to reach the target low. Reaching the average price target will result in a growth of 1512.9% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. CYCC will report FY 2022 earnings on 03/29/2023. Analysts have provided yearly estimates in a range of -$1.67 being high and -$2.62 being low. For CYCC, this leads to a yearly average estimate of -$2.15. The earnings surprise of a firm occurs when the actual results change from the consensus earnings estimate. Cyclacel Pharmaceuticals Inc. surprised analysts by $0.27 when it reported -$0.42 EPS against a consensus estimate of -$0.69. The surprise factor in the prior quarter was $0.14. Based on analyst estimates, the high estimate for the next quarter is -$0.32 and the low estimate is -$0.67. The average estimate for the next quarter is thus -$0.54.
Summary of Insider Activity:
Insiders traded CYCC stock several times over the past three months with 7 Buys and 0 Sells. In these transactions, 118,665 shares were bought while 0 shares were sold. The number of buy transactions has increased to 9 while that of sell transactions has risen to 1 over the past year. The total number of shares bought during that period was 123,665 while 12 shares were sold.